NDAORALCAPSULE
Approved
Feb 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Mechanism of Action
2 (D 2 ) and serotonin type 2 (5HT 2 ) antagonism.
Pharmacologic Class:
Atypical Antipsychotic
Clinical Trials (5)
Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder
Started Dec 2018
23 enrolled
Bipolar Disorder
The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation
Started Oct 2016
1,000 enrolled
Schizophrenia
Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder
Started May 2014
171 enrolled
Bipolar Disorder
Ziprasidone Switching in Response to Adherence and Psychotropic-Related Weight Gain Concerns Among Patients With Bipolar Disorder (Zip Ad)
Started Jan 2011
30 enrolled
Medication AdherenceBipolar Disorder
Efficacy and Safety of Ziprasidone to Treat Depressive Symptoms in Patients With Schizophrenia
Started Dec 2010
120 enrolled
The Primary Evaluation is the Change From Baseline at End of Study for CDSS Total Scores.The Secondary Efficacy Evaluations Include: MADRS, PANSS Total Scores and Subscales and Responder Rate; CGI-S and CGI-I Scales.Safety Evaluations Include: Laboratory Test Abnormalities; BARS and SAS; Physical Examinations; Vital Signs; Electrocardiogram,Etc.+1 more